Working... Menu

Oxaliplatin in Unresectable Hepatocellular Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00280618
Recruitment Status : Completed
First Posted : January 23, 2006
Last Update Posted : September 15, 2009
Information provided by:

Brief Summary:


  • To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin+5-Fluorouracil/Leucovorin


  • Safety and tolerability of this regimen in these patients

Condition or disease Intervention/treatment Phase
Carcinoma, Hepatocellular Drug: Oxaliplatin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Eloxatin + 5-Fluorouracil/Leucovorin in Patients With Unresectable Hepatocellular Carcinoma
Study Start Date : July 2004
Actual Primary Completion Date : November 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Oxaliplatin

Primary Outcome Measures :
  1. Time to Tumor Progression (TTP) and Response Rate: evaluated by RECIST [ Time Frame: During the Study Conduct ]

Secondary Outcome Measures :
  1. Adverse Events collections and evaluation [ Time Frame: From the signature of the informed consent up to the end of the study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically confirmed hepatocellular carcinoma
  • Patients must have measurable disease by CT scan
  • Patients with unresectable, recurrent or metastatic disease may be chemonaive or may be previously treated by chemotherapy.
  • The period of washout of prior chemotherapy must be greater than 4 weeks from date of randomization. The prior chemotherapy should not include platinum compounds.
  • WHO performance status: 0 to 2
  • Patients must have adequate organ and marrow function as defined below:

    • Leukocytes : ≥ 3,000/μl
    • Absolute neutrophil count :≥ 1,500/μl
    • Platelets : ≥ 80,000/μl
    • Total bilirubin : < 3.0g/dl
    • ASAT/ALAT : ≤ 3 times the upper normal limits of the institute
    • Creatinine : < 120μmol/l
  • Patients with no evidence of clinically significant neuropathy.

Exclusion Criteria:

  • Documented allergy to platinum compound or to others study's drugs
  • Pregnant or lactating women or women of childbearing potential (e.g. not using adequate contraception)
  • Hematological disorder or malignancies
  • Metastasis to central nervous system
  • Other serious illness or medical conditions:

    • Active infectious disease
    • Congestive heart failure, or angina pectoris. Previous history of myocardial infarction within 1 year from study entry; uncontrolled hypertension or arrhythmia.
  • Concurrent treatment with any other anticancer therapy
  • Concurrent treatment with other experimental drugs.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00280618

Sponsors and Collaborators
Layout table for investigator information
Study Director: Pingkuan Zhang Sanofi

Layout table for additonal information
Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00280618     History of Changes
Other Study ID Numbers: L_9202
First Posted: January 23, 2006    Key Record Dates
Last Update Posted: September 15, 2009
Last Verified: September 2009

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antineoplastic Agents